WO2022139418A1 - 지방산 도입 고분자 나노 입자 및 이의 용도 - Google Patents
지방산 도입 고분자 나노 입자 및 이의 용도 Download PDFInfo
- Publication number
- WO2022139418A1 WO2022139418A1 PCT/KR2021/019527 KR2021019527W WO2022139418A1 WO 2022139418 A1 WO2022139418 A1 WO 2022139418A1 KR 2021019527 W KR2021019527 W KR 2021019527W WO 2022139418 A1 WO2022139418 A1 WO 2022139418A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nanoparticles
- fatty acid
- calcium carbonate
- adipocytes
- acid
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 94
- 229920000642 polymer Polymers 0.000 title claims abstract description 14
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 77
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 43
- 229930195729 fatty acid Natural products 0.000 claims abstract description 43
- 239000000194 fatty acid Substances 0.000 claims abstract description 43
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 43
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 38
- 229920000249 biocompatible polymer Polymers 0.000 claims abstract description 27
- 239000013078 crystal Substances 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims description 36
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 26
- 239000000839 emulsion Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000001569 carbon dioxide Substances 0.000 claims description 13
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 13
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 10
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 9
- 239000008346 aqueous phase Substances 0.000 claims description 8
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 7
- 230000002378 acidificating effect Effects 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000012071 phase Substances 0.000 claims description 6
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 6
- -1 polyethylene Polymers 0.000 claims description 6
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 6
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 229920000954 Polyglycolide Polymers 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical group O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 3
- 229920002101 Chitin Polymers 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- 239000001263 FEMA 3042 Substances 0.000 claims description 3
- 229920002527 Glycogen Polymers 0.000 claims description 3
- 229920002488 Hemicellulose Polymers 0.000 claims description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 claims description 3
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 3
- 108010013639 Peptidoglycan Proteins 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 229920001400 block copolymer Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 229960002086 dextran Drugs 0.000 claims description 3
- 229940096919 glycogen Drugs 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 3
- 229920005610 lignin Polymers 0.000 claims description 3
- 229920001277 pectin Polymers 0.000 claims description 3
- 239000001814 pectin Substances 0.000 claims description 3
- 235000010987 pectin Nutrition 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920002643 polyglutamic acid Polymers 0.000 claims description 3
- 229920001451 polypropylene glycol Polymers 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 229920002258 tannic acid Polymers 0.000 claims description 3
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims description 3
- 229940033123 tannic acid Drugs 0.000 claims description 3
- 235000015523 tannic acid Nutrition 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 2
- 210000001789 adipocyte Anatomy 0.000 abstract description 61
- 210000004027 cell Anatomy 0.000 abstract description 27
- 230000004130 lipolysis Effects 0.000 abstract description 7
- 239000013589 supplement Substances 0.000 abstract description 4
- 235000005911 diet Nutrition 0.000 abstract description 3
- 230000037213 diet Effects 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 230000003796 beauty Effects 0.000 abstract description 2
- 239000003446 ligand Substances 0.000 abstract description 2
- 239000000047 product Substances 0.000 abstract description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 69
- 235000021314 Palmitic acid Nutrition 0.000 description 34
- 235000010216 calcium carbonate Nutrition 0.000 description 34
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 34
- 239000000243 solution Substances 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 11
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 210000004003 subcutaneous fat Anatomy 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 239000008367 deionised water Substances 0.000 description 8
- 229910021641 deionized water Inorganic materials 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 7
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 235000003441 saturated fatty acids Nutrition 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 238000002296 dynamic light scattering Methods 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000007443 liposuction Methods 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 230000001868 lysosomic effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 238000000942 confocal micrograph Methods 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 238000004880 explosion Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000000694 mesotherapy Methods 0.000 description 2
- 239000012120 mounting media Substances 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920001732 Lignosulfonate Polymers 0.000 description 1
- 235000019738 Limestone Nutrition 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000012993 chemical processing Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000006028 limestone Substances 0.000 description 1
- 230000032630 lymph circulation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- ZSOKVYYWQQGRBY-UHFFFAOYSA-N pentane-1,5-diamine;sodium Chemical compound [Na].NCCCCCN ZSOKVYYWQQGRBY-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 230000004902 response to acidity Effects 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000010557 suspension polymerization reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/85—Polyesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
Definitions
- the present invention relates to fatty acid-introduced polymer nanoparticles and uses thereof.
- Examples of procedures to reduce subcutaneous fat include liposuction in which a cannula is inserted into the subcutaneous fat to suck out fat, a freezing procedure in which a cooling pad is attached to the skin surface to cool and necrosis the subcutaneous fat, and radiofrequency or ultrasound is applied to the subcutaneous fat tissue.
- a thermal heating procedure that removes subcutaneous fat by irradiating and heating and a carboxytherapy procedure that removes fat by gradually injecting carbon dioxide (CO 2 ) into the subcutaneous fat with an injection needle to promote blood circulation and lymph circulation in adipose tissue , and mesotherapy, which injects drugs for the treatment of obesity into subcutaneous fat.
- CO 2 carbon dioxide
- Liposuction which is known to be the most effective among procedures, has disadvantages in the pain accompanying the procedure and future management. Typically, there is bleeding during liposuction and pain during the procedure. This can cause pain even after the procedure, so it may be necessary to take painkillers depending on the individual. In addition, compression garments must be worn for at least a week after the suction operation, and management is required for about a month after the procedure.
- the freezing procedure is simple, but has a disadvantage in that the treatment effect is low.
- Korean Patent Application Laid-Open No. 10-2011-0119640 an invasive procedure in which a probe cooled by circulating a refrigerant inside is inserted into the subcutaneous fat was used.
- the procedure time is shortened compared to the non-invasive cooling procedure, it has a disadvantage in that it requires a considerably long procedure time to prevent necrosis of the subcutaneous fat due to cooling.
- carboxytherapy is a procedure that intensively treats areas where fat is excessively accumulated.
- mesotherapy and carboxytherapy were performed parametrically to increase fat removal efficiency.
- the patent uses a separate syringe needle for each procedure, the internal structure is complicated and a separate incision is made by each needle.
- Belkyra a drug approved as a lipolysis supplement, kills fat cells by destroying the cell membrane of local fat cells.
- Belkyra has the disadvantage that it can be used only for double chin surgery.
- these drugs non-specifically destroy cell membranes, it is reported that the risk of breast cancer or colorectal cancer increases because it has a large effect on surrounding cells as well as adipocytes, and may have adverse effects on surrounding tissues.
- the present invention is to provide polymer nanoparticles for decomposing local fat and uses thereof.
- the present invention provides nanoparticles comprising calcium carbonate crystals, biocompatible polymers and fatty acids, wherein the calcium carbonate is incorporated inside the nanoparticles, and the fatty acids are exposed on the surface of the nanoparticles do.
- the existing local lipolysis procedure it is a method of treatment by directly injecting a drug into the area where fat has accumulated with an injection needle.
- the nerve When the nerve is touched, there is a problem of numbness or the risk of nerve damage.
- the present inventors use nanoparticles containing calcium carbonate crystals, biocompatible polymers and fatty acids to specifically enter the interior of fat cells by fatty acids exposed on the surface of nanoparticles. The present invention was completed by confirming that particles can be introduced.
- calcium carbonate (Calcium Carbonate) crystals is distinguished from precipitated calcium carbonate produced by chemical processing, and generally refers to those prepared by mechanically grinding and classifying high-purity crystalline limestone. .
- the nanoparticles of the present invention have a form in which the calcium carbonate crystals are embedded in the biocompatible polymer, which is a hard shell formed by the biocompatible polymer. It means a solid colloidal structure that is evenly embedded without significant difference in distribution probability from the center of the spherical structure to the outer surface.
- nanoparticles of the present invention in an acidic environment, calcium carbonate crystals embedded in the particles cause a reaction to generate carbon dioxide gas.
- the nanoparticles of the present invention are not in the form of a core-shell containing calcium carbonate in the layered membrane structure, but in the form in which the calcium carbonate crystals are embedded in the solid crystals filled inside. That is, when the calcium carbonate crystals embedded in the nanoparticles generate carbon dioxide gas to be differentiated from the structure in which the gas generated inside leaks out at the same time as the gas is generated, the internal pressure of the nanoparticles gradually increases, Finally, it induces the explosion of nanoparticles. Due to these properties, it is possible to simultaneously achieve the effect of releasing carbon dioxide gas bubbles and hitting the cells by the explosion of nanoparticles.
- the biocompatible polymer of the present invention is surface-modified with a fatty acid.
- the fatty acid is mixed with the biocompatible polymer to form the spherical structure, and the fatty acid has a form exposed on the surface of the structure.
- Fatty acids of the present invention may include saturated fatty acids and unsaturated fatty acids, preferably C 12 to C 20 saturated or unsaturated fatty acids.
- the fatty acids exposed to the surface of the nanoparticles of the present invention have adipocyte targeting directivity.
- the fatty acid on the surface of the nanoparticles reacts with fatty acid transporter proteins present in the cell membrane of adipocytes so that the nanoparticles are introduced into the adipocytes by intracellular absorption. Therefore, the nanoparticles surface-modified with fatty acids are selectively absorbed/accumulated into adipocytes or adipose tissue, and generate carbon dioxide gas in adipocytes to transform and destroy the nanoparticle structure, rapidly ejected, and physically attach to adipocytes. Adipose tissue can be reduced by decomposing it or causing necrotic necrosis.
- the biocompatible polymer of the present invention means a polymer having tissue compatibility and blood compatibility that does not destroy tissue or coagulate blood in contact with living tissue or blood, and the emulsion method of the present invention As long as it can form a solid structure in which calcium carbonate crystals are incorporated, it can be appropriately selected without any particular limitation.
- the biocompatible polymer of the present invention is polylactide (PLA), polyglycolide (PGA), polylactide-polyglycolide copolymer (PLGA), starch, glycogen, chitin, pepti Doglycan, lignosulfonate, tannic acid, lignin, pectin, polyethylene glycol, polyethylene oxide, polyvinyl alcohol, polyethylene oxide-polypropylene oxide block copolymer, cellulose, hemicellulose, heparin, hyaluronic acid, dextran or alginate It is a polymer with a structure.
- polylactide-polyglycolide copolymer (PLGA) may be used.
- the diameter of the nanoparticles of the present invention may be 100-300 nm, preferably 120-290 nm, more preferably 150-280 nm, even more preferably 200-260 nm can be In the above diameter range, it is possible to maximize the cell striking effect that can induce necrotic death of fat cells.
- the weight ratio of the fatty acid and the biocompatible polymer may be 0.01:1 to 0.5:1 (fatty acid: polymer). Preferably, it may be 0.05:1 to 0.15:1. Within this weight ratio, targeting to adipocytes and cell viability can be increased. When the content of fatty acid is greater than the above range, the diameter of the nanoparticles may increase, but a lot is lost due to the low temperature of the manufacturing process, and the stability of the prepared nanoparticles may be deteriorated.
- the weight ratio of the calcium carbonate crystals and the biocompatible polymer may be 0.001:1 to 1:1 (calcium carbonate: polymer).
- the weight ratio of the calcium carbonate crystals to the biocompatible polymer is 0.01:1 to 0.8:1, more preferably 0.1:1 to 0.6:1.
- the calcium carbonate crystals and the biocompatible polymer corresponding to the above weight ratio can maximize the fat cell reduction effect.
- the ratio of calcium carbonate crystals to the biocompatible polymer does not significantly affect the diameter of the gas-generating nanoparticles produced.
- the present invention provides a composition for decomposing fat comprising the nanoparticles described above.
- the composition for lipolysis of the present invention has the effect of specifically releasing carbon dioxide from the environment within the fat cells, and unlike the conventional local lipolysis treatment, it is possible to target adipose tissue.
- the present invention provides a pharmaceutical composition for preventing or treating obesity comprising the above-described nanoparticles and / or a composition comprising the same.
- the present invention provides a method for producing nanoparticles comprising the steps of:
- step (b) mixing the emulsion of step (a) and the second aqueous phase to form a water-in-oil-in-water double emulsion (w/o/w);
- step (c) solidifying the double emulsion of step (b).
- the "first aqueous phase” is an aqueous solvent (pH 7.0-8.0) containing a calcium carbonate slurry, specifically, for example, distilled water in which calcium carbonate crystals are suspended, physiological saline (PBS), An aqueous PVA solution or the like may be used.
- the "oil phase” of step (a) of the present invention may use a fatty acid and a biocompatible polymer dissolved in a hydrophobic and volatile organic solvent that is immiscible with an aqueous phase.
- a fatty acid and a biocompatible polymer in methylene What is dissolved in chloride, chloroform, dimethylformamide, ethyl acetate, acetone, acetonitrile, tetrahydrofuran, dimethyl sulfoxide, or a mixed solvent thereof can be used.
- Mixing of the first aqueous phase and oil phase in step (a) of the present invention may be preferably carried out using mechanical stirring, for example, it may be carried out using an ultrasonic crusher, a homomixer, a stirrer, and the like.
- the single emulsion (w/o) prepared through step (a) of the present invention is mixed with the second aqueous phase to form a double emulsion (w/o/w).
- aqueous surfactant solution such as polyvinyl alcohol, poloxamer, or polyvinylpyrrolidone may be used.
- the resulting double emulsion can be solidified through evaporation or extraction of an organic solvent.
- the weight ratio of the fatty acid and the biocompatible polymer may be 0.01:1 to 0.2:1 (fatty acid: polymer). Preferably, it may be 0.05:1 to 0.15:1.
- the calcium carbonate crystal and the biocompatible polymer may have a weight ratio of 0.001:1 to 1:1 (calcium carbonate: polymer), preferably 0.01:1 to 0.8:1, more preferably 0.1:1 to 0.6 It can be :1.
- the present invention nanoparticle manufacturing method relates to a method for manufacturing nanoparticles, which is another aspect of the present invention, and overlapping content with nanoparticles will be omitted to avoid excessive complexity in the description of the present specification.
- the high-rich nanoparticles according to the present invention can decompose fat through adipocyte necrosis by specifically incorporating adipocytes while circulating in the body to generate carbon dioxide in the cells.
- a ligand fatty acid
- the effect on surrounding tissues and cells can be minimized, and by doing so, side effects to drugs can be minimized, and safer procedures are possible.
- Possible product development is possible.
- the nanoparticles can be generally applied to areas such as the chin, thigh, arm, and stomach, where the frequency of treatment is high.
- the nanoparticles according to the present invention can be manufactured as an injectable preparation, and are applied to the field of diet beauty and obesity treatment, and are a local lipolysis supplement, formulation corrector, or diet cosmetic product that decomposes local fat through necrosis of local fat. etc. can be used.
- FIG. 1 is a schematic diagram showing the incorporation process of fatty acid-introduced nanoparticles (a), fatty acid (b), and fatty acid-introduced nanoparticles (b) into adipocytes according to an example of the present invention.
- FIG. 2 is a diagram showing the size distribution of (a) PNP, (b) GNP, (c) PA-GNP2, and (d) PA-GNP10 measured by DLS.
- FIG 3 shows SEM images of (a) PNP, (b) GNP, (c) PA-GNP2 and (d) PA-GNP10.
- Figure 4 shows the 1H NMR spectrum of the nanoparticles according to the palmitic acid concentration.
- FIG. 10 shows confocal microscopy images of 3T3-L1 adipocytes treated with PNP and PA-PNP conjugated with alexa 488 cadaverine.
- FIG. 11 shows confocal microscopy images of 3T3-L1 adipocytes treated with alexa 488 cadaverine-conjugated PNP and various types of FA-PNP.
- Poly(DL-lactide-co-glycolide) (PLGA, Mw 6400, 50:50, 0.15-0.25 dL/g, carboxylate terminus) was purchased from Lactel Absorbable Polymers (Birmingham, AL, USA).
- Poly(vinyl alcohol) (PVA, Mw 30000-70000, 87-90 % hydrolyzed), dichloromethane (methylene chloride, MC), calcium carbonate (CaCO 3 ), palmitic acid (PA), oil red O, hydroxide Sodium (NaOH), hydrochloride (HCl), sodium acetate (anhydrous), acetic acid, dimethylsulfoxide (DMSO), 3-isobutyl-1-methyl-xanthine (IBMX), insulin, dexamethasone, Dulbecco's Phosphate Buffered Saline (DPBS), penicillin-streptomycin glutamine, and 10% formalin solution were purchased from Sigma-Aldrich (St. Louis, MO, USA).
- 2-propanol (isopropanol, 99.5%) was purchased from Samcheon (Gangnam, Seoul).
- CellTiter 96 ® Aqueous One Solution (MTS assay) was purchased from Promega (Madison, WI, USA).
- Dulbecco's modified Eagle's medium (DMEM, 4.5 g/L, D-glucose) was purchased from Wellgene (Gyeongsan, Gyeongbuk).
- Fetal bovine serum (FBS) and bovine calf serum (CS) were purchased from Gibco (Grand Island, NY, USA). Trypsin-ethylenediaminetetraacetic acid and Hoechst 33342 were purchased from Thermo Fisher Scientific (Waltham, MA, USA).
- Alexa fluorTM 488 cadaverine sodium salt and lysotracker red DND-99 were purchased from Invitrogen (Eugene, OR, USA).
- VECTASHIELD ® Antifade mounting medium was purchased from Vector Laboratories (Burlingame, CA, USA). Water was distilled and deionized using a Milli-Q (R) System (Millipore; Billerica, Massachusetts, USA) and purified RO MAX (Human Science; Hanam, Gyeonggi, Korea). Mouse C57BL/6 was purchased from Orient (Seongnam, Gyeonggi).
- Fatty acid modified gas-generating PLGA nanoparticles were prepared by water-in-oil-in-water (W/O/W) double emulsion and solvent evaporation methods. Fatty acids physically modified the GNP surface. A fatty acid solution dissolved in 10 % w/v dichloromethane was mixed with a PLGA solution (5 % w/v) for at least 4 hours (FA-PLGA solution).
- Another emulsion (W 1 /O/W 2 ) was made by pouring this emulsion (W 1 /O) into a 4% PVA solution used as a suspension polymerization aid and emulsifying it with a sonicator at 35 W output for 2 minutes. The complete double emulsion was added to the 1% PVA solution and stirred overnight to evaporate the remaining dichloromethane. Unloaded CaCO 3 was removed by ultracentrifugation at 4000 g for 1 minute. Thereafter, the supernatant was ultracentrifuged at 31,000 g for 30 minutes to collect nanoparticles and washed 4 times with deionized water.
- FA-GNP was stored at 4 °C after freeze-drying (Ilshin Biobase freeze dryer, Dongducheon-si, Gyeonggi-do).
- FA-PLGA nanoparticles (FA-PNP) without CaCO 3 were prepared in the same manner and used as a control.
- PLGA nanoparticles containing calcium carbonate were prepared by a W/O/W double emulsification method and used as gas generating nanoparticles (GNPs).
- PLGA nanoparticles containing no calcium carbonate were also prepared and used as a control.
- the loading content of CaCO 3 in GNPs was 55.0% (CaCO 3 /PLGA; wt/wt%)
- the average diameter of GNPs was 246.8 nm.
- PDI polydispersity index
- the morphology of nanoparticles was observed with a scanning electron microscope (SEM) (S-4800 U field emission scanning electron microscope, Hitachi, Tokyo, Japan).
- SEM scanning electron microscope
- NMR and py-GC/MS were used for the qualitative analysis of palmitic acid. Spectra were acquired using NMR spectroscopy. For all samples DMSO was used as solvent and diluted to an equivalent concentration of 2 mg/mL.
- Spectra were also acquired using py-GC/MS and 4 mg was used for all samples.
- PA-GNP was dissolved in 1M NaOH solution for 1 hour and neutralized with 1M HCl solution.
- the CaCO 3 concentration percentage of the nanoparticle solution was estimated using a calcium colorimetric analysis kit from Bio Vision (Palo Alto, CA, USA) and calculated as a weight fraction.
- Palmitic acid a saturated fatty acid commonly found in animals, was selected and used for surface modification of PLGA nanoparticles because it is less sensitive to light, air and heat than oleic acid, another abundant fatty acid in animals. PA was physically bound to PLGA nanoparticles in various weight ratios for enhanced adipocyte uptake. Palmitic acid-modified gas-generating PLGA nanoparticles (PA-GNP) were prepared by self-assembly between PA and PLGA nanoparticles in the O phase during emulsification. The number after PA-GNP indicates the supply ratio of palmitic acid and PLGA (Table 1). PLGA itself and unmodified nanoparticles (GNPs) were used as controls.
- PA Palmitic acid
- GNP unmodified nanoparticles
- PA-PNP The morphology of PA-PNP was also observed by scanning electron microscopy. Even when palmitic acid was added, PA-PNP was still spherical compared to PNP and there was no significant change in size ( FIGS. 3c and 3d ). The size change under acidic conditions was similar to that of GNPs even when palmitic acid was attached. Through the above results, it was confirmed that the surface modification by palmitic acid did not significantly affect the physical properties such as the size, shape, and gas generating ability of GNPs.
- NIH-3T3 cells fibroblasts
- ATCC American Type Culture Collection
- PS penicillin and streptomycin
- C2C12 cells myocytes
- 3T3-L1 adipocytes were purchased from ATCC and maintained in 10% CS medium at 37° C. and 5% CO 2 condition.
- adipocyte differentiation was initiated by culturing in growth medium (MDI medium) for 2 days. Cells were cultured for 2 days in DMEM medium containing 10% FBS and 0.1% insulin. Finally, the differentiated cells were cultured in DMEM medium containing 10% FBS, and the medium was replaced every other day.
- IBMX 0.5 mM
- insulin 1 ⁇ g/mL
- dexamethasone 1 ⁇ M
- Oil Red O staining was used to determine the degree of adipocyte differentiation and mark lipid droplets.
- Oil Red O stock solution was prepared by dissolving 0.7 g of Oil Red O powder in 200 mL of isopropane, stirring overnight, filtration through a 0.22 ⁇ m syringe filter, and storing at 4°C.
- An Oil Red O working solution was prepared by mixing the stock solution and deionized water in a 3:2 ratio, left at room temperature (RT) for 20 minutes, and filtered through a 0.22 ⁇ m syringe filter before use. Cells were washed with 10% formalin for 5 min at RT and fixed with 10% formalin for 1 h at RT.
- Oil Red O working solution was added for 10 minutes. Residues of the Oil Red O stock solution were removed by washing the cells at least 4 times with deionized water. After photographing under a microscope, it was completely dried again. Oil Red O was eluted with 100% isopropanol by pipetting up and down several times, followed by measurements at 500 nm using an ultraviolet/visible spectrophotometer (SpectraMax ABS, Molecular Devices, San Jose, CA, USA).
- GNP did not affect the cell viability of all other cell lines such as adipocytes, adipocytes, stem cells, fibroblasts and myoblasts. This suggests that the cells cannot only uptake GNPs and that carbon dioxide gas production does not occur at biological pH.
- PA-GNP when PA-GNP was used, the presence of PA did not significantly affect the other cell lines, but the viability was particularly reduced in adipocytes. Based on these results, it was found that PA-GNP is effective in adipocytes, where fatty acids are most absorbed. In addition, it was confirmed that the acidic state of endocytosis generated in the process of absorbing fatty acids promotes carbon dioxide gas production and greatly reduces cell viability.
- the labeled nanoparticles were collected by ultracentrifugation at 31,000 g for 15 minutes and washed three times with deionized water.
- Alexa 488 cadaverine-PA-PNP was stored at 4°C after freeze-drying.
- 3T3-L1 adipocytes were seeded into confocal dishes at the recommended seeding density of 8 ⁇ 10 4 cells and differentiated as described in the section above. Lysotracker red (50 nM) and alexa 488 cadaverine-PA-PNP (0.5 mg/mL) containing medium were treated with adipocytes for 24 hours. After that, the adipocytes were washed 3 times with DPBS to remove the remaining nanoparticles and treated with HOECHST (1 ⁇ g/mL) for 15 minutes to stain the nucleus.
- 3T3-L1 preadipocytes were cultured in CS medium and differentiated into adipocytes in FBS medium. Lipid droplets were observed in the cytoplasm after adipocyte differentiation and detected by Oil Red O staining (Fig. 7). The accumulation of lipid droplets was investigated in stages from before differentiation to 12 days after differentiation.
- the cytotoxicity of nanoparticles was evaluated through MTS analysis of 3T3-L1 adipocytes.
- untreated cells were used, and cells treated with PNP, GNP, PA-PNP2, and PA-PNP10 did not show a significant change according to the sample concentration ( FIG. 8 ).
- PLGA, PA and CaCO 3 used for nanoparticle production do not have appreciable toxicity.
- the concentration of PA increased, the cell viability of the cells treated with PA-GNP decreased ( FIG. 9 ). This was considered to be of significant significance and was used for further experiments.
- the cell viability tended to be the lowest when the PA/PLGA ratio was 1, but the properties of nanoparticles were too oily for the experiment, so they were excluded from the experimental group.
- the specific cellular uptake of PA-PLGA nanoparticles into 3T3-L1 adipocytes was examined by confocal microscopy using an Alexa 488 cadaverine-PA-PNP.
- Cellular uptake of PA-PNP into 3T3-L1 adipocytes was clearly observed compared with nanoparticles with unmodified surface (Fig. 10).
- the lysotracker probe used in this experiment is partially neutralized at neutral pH and has a weak base that can freely penetrate cell membranes. It is also highly selective for organelles with acidity. Therefore, in this experiment, the lysosomes showing the acidic pH inside the cell are selectively stained and appear red.
- nanoparticles whose surface has been modified with the green label of Alexa 488 cadaverine are absorbed by various mechanisms, enter endosomes, and eventually lead to co-localization with lysosomes. Therefore, when lysosomes and nanoparticles meet, yellow color indicates successful absorption. And this could also be expected in the future due to the generation of carbon dioxide gas in PA-GNPs and apoptosis of adipocytes.
- FA-PLGA nanoparticles (FA-PNP) without CaCO 3 were prepared using fatty acids having various lengths of carbon chains, and endocytosis of adipocytes was evaluated.
- FA-PLGA nanoparticles were prepared using fatty acids and PLGA.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Abstract
Description
Claims (13)
- 탄산 칼슘(Calcium Carbonate) 결정, 생체적합성 고분자 및 지방산을 포함하는 나노 입자로, 상기 탄산칼슘은 나노 입자의 내부에 합입되어 있고, 지방산은 나노 입자의 표면에 노출되어 있는 나노 입자.
- 제1항에 있어서,상기 나노 입자는 산성 환경에서 이산화탄소를 방출하는 나노 입자.
- 제1항에 있어서,제 1 항에 있어서, 상기 생체적합성 고분자는 폴리락타이드(PLA), 폴리글리콜라이드(PGA), 폴리락타이드-폴리글리콜라이드 공중합체(PLGA), 녹말, 글리코겐, 키틴, 펩티도글리칸, 리그노 설포네이트, 탄닌산, 리그닌, 펙틴, 폴리에틸렌글라이콜, 폴리에틸렌옥사이드, 폴리비닐알코올, 폴리에틸렌옥사이드-폴리프로필렌옥사이드 블록 공중합체, 셀룰로오스, 헤미 셀룰로오스, 헤파린, 히아루론산, 덱스트란 또는 알지네이트 구조를 갖는 중합체인 나노 입자.
- 제 1항에 있어서, 상기 나노 입자의 직경은 100-300 nm인 나노 입자.
- 제 1항에 있어서, 상기 지방산은 포화 지방산 또는 불포화 지방산인 나노 입자.
- 제 1항에 있어서, 상기 지방산 및 생체적합성 고분자는 중량비가 0.01:1 내지 0.2:1인 나노 입자.
- 제1항 내지 제6항 중 어느 한 항에 따른 나노 입자를 포함하는 지방 분해용 조성물.
- 제7항의 지방 분해용 조성물을 포함하는 비만 예방 및 치료용 약학적 조성물.
- 하기의 단계를 포함하는 제 1항 내지 제6항 중 어느 한 항의 나노 입자의 제조 방법:(a) 탄산칼슘 결정을 포함하는 제1 수상(water phase)과 지방산 및 생체적합성 고분자를 포함하는 유상(oil phase)을 혼합하여 유중 수형의 단일 에멀젼(W/O)을 형성하는 단계;(b) 단계(a)의 에멀젼과 제2 수상을 혼합하여 수중유중수형의 이중 에멀젼(W/O/W)을 형성하는 단계; 및(c) 단계(b)의 이중 에멀젼을 고형화시키는 단계.
- 제1항에 있어서,제 9항에 있어서, 상기 생체적합성 고분자는 폴리락타이드(PLA), 폴리글리콜라이드(PGA), 폴리락타이드-폴리글리콜라이드 공중합체(PLGA), 녹말, 글리코겐, 키틴, 펩티도글리칸, 리그노 설포네이트, 탄닌산, 리그닌, 펙틴, 폴리에틸렌글라이콜, 폴리에틸렌옥사이드, 폴리비닐알코올, 폴리에틸렌옥사이드-폴리프로필렌옥사이드 블록 공중합체, 셀룰로오스, 헤미 셀룰로오스, 헤파린, 히아루론산, 덱스트란 또는 알지네이트 구조를 갖는 중합체인 나노 입자의 제조 방법.
- 제 9항에 있어서, 상기 방법에 의해 제조된 나노 입자의 직경은 100-300 nm인 나노 입자의 제조 방법.
- 제 9항에 있어서, 상기 지방산은 포화 지방산 또는 불포화 지방산인 나노 입자의 제조 방법.
- 제 9항에 있어서, 상기 생체적합성 고분자 및 지방산은 중량비가 0.01:1 내지 0.2:1로 혼합된 것인 나노 입자의 제조 방법.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21911485.7A EP4268807A1 (en) | 2020-12-24 | 2021-12-21 | Fatty acid-modified polymer nanoparticles, and use thereof |
CA3203170A CA3203170A1 (en) | 2020-12-24 | 2021-12-21 | Fatty acid- modified polymer nanoparticles, and use thereof |
MX2023007499A MX2023007499A (es) | 2020-12-24 | 2021-12-21 | Nanoparticulas de polimero modificadas con acidos grasos, y uso de las mismas. |
JP2023539007A JP2024500500A (ja) | 2020-12-24 | 2021-12-21 | 脂肪酸導入高分子ナノ粒子およびその用途 |
AU2021409688A AU2021409688A1 (en) | 2020-12-24 | 2021-12-21 | Fatty acid-modified polymer nanoparticles, and use thereof |
US18/269,543 US20240066055A1 (en) | 2020-12-24 | 2021-12-21 | Fatty acid-modified polymer nanoparticles, and use thereof |
CN202180086998.XA CN116669766A (zh) | 2020-12-24 | 2021-12-21 | 脂肪酸引入高分子纳米粒子及其用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0183085 | 2020-12-24 | ||
KR20200183085 | 2020-12-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022139418A1 true WO2022139418A1 (ko) | 2022-06-30 |
Family
ID=82158175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/019527 WO2022139418A1 (ko) | 2020-12-24 | 2021-12-21 | 지방산 도입 고분자 나노 입자 및 이의 용도 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20240066055A1 (ko) |
EP (1) | EP4268807A1 (ko) |
JP (1) | JP2024500500A (ko) |
KR (1) | KR20220092398A (ko) |
CN (1) | CN116669766A (ko) |
AU (1) | AU2021409688A1 (ko) |
CA (1) | CA3203170A1 (ko) |
MX (1) | MX2023007499A (ko) |
WO (1) | WO2022139418A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116327708A (zh) * | 2023-03-31 | 2023-06-27 | 西南交通大学 | 纳米颗粒的制备方法以及纳米载药颗粒的制备方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992002587A1 (en) * | 1990-08-06 | 1992-02-20 | Pfizer Inc. | Calcium carbonate treated with fatty acids, manufacture and use |
KR20070084319A (ko) * | 2004-10-18 | 2007-08-24 | 올레오일-에스트론 디벨롭먼츠 에스엘 | 포유동물의 체중 감소를 위한 에스트로겐의 지방산에스테르 및 열발생 화합물의 사용 방법 및 이를 함유하는조성물 |
KR100772961B1 (ko) | 2006-08-07 | 2007-11-02 | (주)엠큐어 | 메조테라피/카복시테라피 시술용 복합기 |
KR20110119640A (ko) | 2008-12-22 | 2011-11-02 | 마이오우사이언스, 인크. | 냉매 공급원과 전원이 통합된 한랭수술 시스템 |
KR101613606B1 (ko) * | 2014-06-13 | 2016-04-20 | 한양대학교 산학협력단 | 가스-생성 나노파티클 |
WO2020010059A1 (en) * | 2018-07-02 | 2020-01-09 | Aptamir Therapeutics, Inc. | Targeted delivery of therapeutic agents to human adipocytes |
KR102112702B1 (ko) * | 2019-12-19 | 2020-05-19 | (주)슈퍼노바 바이오 | 표면 개질된 가스-생성 나노입자를 이용한 지방 분해용 조성물 |
JP2020178709A (ja) * | 2014-07-31 | 2020-11-05 | アモーフィカル リミテッド. | カプセル化された非晶質炭酸カルシウム組成物 |
-
2021
- 2021-12-21 KR KR1020210183501A patent/KR20220092398A/ko active Search and Examination
- 2021-12-21 CA CA3203170A patent/CA3203170A1/en active Pending
- 2021-12-21 CN CN202180086998.XA patent/CN116669766A/zh active Pending
- 2021-12-21 EP EP21911485.7A patent/EP4268807A1/en active Pending
- 2021-12-21 WO PCT/KR2021/019527 patent/WO2022139418A1/ko active Application Filing
- 2021-12-21 MX MX2023007499A patent/MX2023007499A/es unknown
- 2021-12-21 JP JP2023539007A patent/JP2024500500A/ja active Pending
- 2021-12-21 AU AU2021409688A patent/AU2021409688A1/en active Pending
- 2021-12-21 US US18/269,543 patent/US20240066055A1/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992002587A1 (en) * | 1990-08-06 | 1992-02-20 | Pfizer Inc. | Calcium carbonate treated with fatty acids, manufacture and use |
KR20070084319A (ko) * | 2004-10-18 | 2007-08-24 | 올레오일-에스트론 디벨롭먼츠 에스엘 | 포유동물의 체중 감소를 위한 에스트로겐의 지방산에스테르 및 열발생 화합물의 사용 방법 및 이를 함유하는조성물 |
KR100772961B1 (ko) | 2006-08-07 | 2007-11-02 | (주)엠큐어 | 메조테라피/카복시테라피 시술용 복합기 |
KR20110119640A (ko) | 2008-12-22 | 2011-11-02 | 마이오우사이언스, 인크. | 냉매 공급원과 전원이 통합된 한랭수술 시스템 |
KR101613606B1 (ko) * | 2014-06-13 | 2016-04-20 | 한양대학교 산학협력단 | 가스-생성 나노파티클 |
JP2020178709A (ja) * | 2014-07-31 | 2020-11-05 | アモーフィカル リミテッド. | カプセル化された非晶質炭酸カルシウム組成物 |
WO2020010059A1 (en) * | 2018-07-02 | 2020-01-09 | Aptamir Therapeutics, Inc. | Targeted delivery of therapeutic agents to human adipocytes |
KR102112702B1 (ko) * | 2019-12-19 | 2020-05-19 | (주)슈퍼노바 바이오 | 표면 개질된 가스-생성 나노입자를 이용한 지방 분해용 조성물 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116327708A (zh) * | 2023-03-31 | 2023-06-27 | 西南交通大学 | 纳米颗粒的制备方法以及纳米载药颗粒的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
MX2023007499A (es) | 2023-07-05 |
JP2024500500A (ja) | 2024-01-09 |
AU2021409688A1 (en) | 2023-07-20 |
US20240066055A1 (en) | 2024-02-29 |
KR20220092398A (ko) | 2022-07-01 |
CA3203170A1 (en) | 2022-06-30 |
CN116669766A (zh) | 2023-08-29 |
EP4268807A1 (en) | 2023-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | 3D printed hydrogel/PCL core/shell fiber scaffolds with NIR-triggered drug release for cancer therapy and wound healing | |
Xie et al. | Epithelia transmembrane transport of orally administered ultrafine drug particles evidenced by environment sensitive fluorophores in cellular and animal studies | |
Ta et al. | Chitosan nanoparticles for enhancing drugs and cosmetic components penetration through the skin | |
Wei et al. | Dissolving microneedles integrated with pH-responsive micelles containing AIEgen with ultra-photostability for enhancing melanoma photothermal therapy | |
Xie et al. | Enhanced in vitro efficacy for inhibiting hypertrophic scar by bleomycin-loaded dissolving hyaluronic acid microneedles | |
Lu et al. | Enhanced anticancer effect of ROS-boosted photothermal therapy by using fucoidan-coated polypyrrole nanoparticles | |
CN102327230B (zh) | 一种包裹紫杉烷类药物的蛋白纳米颗粒及其制备方法 | |
US8790695B2 (en) | Medicinal carriers, and preparation method and uses thereof | |
WO2022139418A1 (ko) | 지방산 도입 고분자 나노 입자 및 이의 용도 | |
CN111973573B (zh) | 一种磷酸钙纳米颗粒及其制备方法和应用 | |
Chen et al. | Self-implanted tiny needles as alternative to traditional parenteral administrations for controlled transdermal drug delivery | |
CN113456613A (zh) | 一种近红外光激活型巨噬细胞-纳米前药靶向递药系统的构建及其应用 | |
CN102357077B (zh) | 一种包裹难溶性药物的蛋白纳米颗粒及其制备方法 | |
Sun et al. | Laden nanofiber capsules for local malignancy chemotherapy | |
Wang et al. | MET-targeted NIR II luminescence diagnosis and up-conversion guided photodynamic therapy for triple-negative breast cancer based on a lanthanide nanoprobe | |
Liu et al. | Biodegradable and dissolvable resveratrol nanocrystals non-silicon microneedles for transdermal drug delivery | |
Luo et al. | Tailoring hyaluronic acid hydrogels for biomedical applications | |
Zhou et al. | Electrospun medicated gelatin/polycaprolactone Janus fibers for photothermal-chem combined therapy of liver cancer | |
CN113041212B (zh) | 一种自组装凝胶祛痘微针贴片及其的制备方法和应用 | |
CN113521311A (zh) | 一种具有肿瘤靶向功能的双模态成像指导的聚合物囊泡及其制备方法和应用 | |
CN102357076B (zh) | 一种包裹难溶性药物的蛋白纳米颗粒的制备方法 | |
Singh et al. | Uric acid released from poly (ε‐caprolactone) fibers as a treatment platform for spinal cord injury | |
Wang et al. | The impact of dexmedetomidine-loaded nano-microsphere combined with percutaneous acupoint electrical stimulation on the postoperative cognitive function of elderly patients with hip fracture | |
Lee et al. | Microcurrent Cloth-Assisted Transdermal Penetration and Follicular Ducts Escape of Curcumin-Loaded Micelles for Enhanced Wound Healing | |
Wang et al. | Enhanced biocompatibility of silk sericin/caffeic acid nanoparticles by red blood cell membranes cloaking |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21911485 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2023/007499 Country of ref document: MX Ref document number: 202180086998.X Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 3203170 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023539007 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2021409688 Country of ref document: AU Date of ref document: 20211221 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021911485 Country of ref document: EP Effective date: 20230724 |